Disclosures: Vaclav Smid: Nothing to Disclose, Ksenyia Dryahina: Nothing to Disclose, Barbora Novkov: Nothing to Disclose, Stefan Swift: Nothing to Disclose, Simon Dostal: Nothing to Disclose, Sarka Svobodova: Nothing to Disclose, Martin Lenicek: Nothing to Disclose, Patrik Spanel: Nothing to Disclose, Radan Bruha: Nothing to Disclose 855 BASELINE CHARACTERISTICS IN WELL-COMPENSATED NASH CIRRHOSIS PATIENTS DIAGNOSED WITH OR WITHOUT A LIVER BIOPSY IN MAESTRO-NASH-OUTCOMES, A CLINICAL OUTCOME PHASE 3 STUDY ASSESSING THE EFFECT OF RESMETIROM IN WELL COMPENSATED NASH CIRRHOSIS Meena Bansal 1 Jrn Schattenberg 2 Kris Kowdley 3 Mazen Noureddin 4 Rohit Loomba 5 Rebecca Taub 6 Dominic Labriola 6 David Schneider 6 , 1 Icahn School of Medicine at Mount Sinai (ISMMS), 2 Saarland University Medical Center, Homburg and Saarland University, 3 Liver Institute Northwest, 4 Houston Methodist Hospital, 5 University of California, San Diego, 6 Madrigal Pharmaceuticals Background: MAESTRO- NASH Outcomes (NCT05500222) is a multi-national, multicenter, double-blind, randomized, placebo-controlled study in well-compensated NASH cirrhosis
Both genetic vulnerability and environmental factors could help explain the differences in the prevalence of these disorders between genders [50,51,52]
Join Now 1 offers Available for you MYSHOPCLUES Get flat 10 Percent off on all Prepaid Orders Use Code "MYSHOPCLUES" Min
The product is intended for multidose use and has been developed under strict quality control in Sweden
Se utilizan nmeros de lote individuales para garantizar la trazabilidad a lo largo de todo el proceso de produccin y envasado
